Healthcare / BiotechnologyKOSDAQ
$16830.00
-60.00 (-0.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-7.3B · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$251.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-158.0%
↓Gross Margin
81.7%
↑Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.1%
FCF CAGR
—
FCF margin
-249.4%
FCF / Net income
0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.91B · net income $-42.02B · FCF $-7.26B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.91B | $2.91B | $5.76B | $3.48B | $4.15B |
| Net Income | $-42.02B | $-42.02B | $-6.44B | $-20.87B | $-18.80B |
| EBITDA | $-38.83B | $-38.83B | $-4.36B | $-18.37B | $-15.74B |
| EPS | -2822.00 | -2822.00 | -511.00 | -1667.00 | -1530.00 |
| Gross Margin | 81.7% | 81.7% | 75.9% | 68.7% | 32.2% |
| Operating Margin | -318.2% | -318.2% | -146.6% | -291.2% | -453.7% |
| Net Margin | -1442.7% | -1442.7% | -111.8% | -599.9% | -453.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.04 | 0.12 | 0.40 |
| Current Ratio | 16.45 | 16.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.26B | $-7.26B | $-7.00B | $-7.80B | $-11.20B |
| Returns | |||||
| ROE | -158.0% | -158.0% | -35.1% | -89.2% | -153.0% |
| Valuation | |||||
| P/B | 9.42 | 9.42 | 5.54 | 7.66 | — |
| Growth & Yield | |||||
| Revenue Growth | -49.5% | -49.5% | 65.6% | -16.2% | — |
| EPS Growth | -452.3% | -452.3% | 69.3% | -9.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+120.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-511.00 → -2822.00
Residual
+120.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.